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ABSTRACT 
 
Alleged patent infringers may bring declaratory judgment actions 
against patentees when actual controversies exist over infringement or 
validity. Such declaratory judgment actions are important strategic 
tools because they allow alleged infringers to take initiative and bring 
actions, thereby eliminating the risk of doing business without knowing 
whether continued product use would constitute infringement. 
Declaratory judgment actions also provide alleged infringers an 
opportunity to choose the forum in which to bring their suits. In order 
to bring such an action, however, there must be an actual controversy 
between the parties to establish standing. The United States Supreme 
Court’s 2007 decision in MedImmune v. Genentech made it easier 
for alleged infringers to obtain declaratory judgments without actually 
terminating or breaching license agreements. The Court held that all 
circumstances should be considered when determining whether an 
actual controversy exists. The United States Court of Appeals for the 
Federal Circuit, relying on MedImmune, has since considered what 
communication between parties is sufficient to establish the existence 
of such a controversy. This Article analyzes those decisions, discusses 
possible implications, and describes how the Federal Circuit has finally 
embraced the “all circumstances” test for determining whether a 
sufficient controversy exists to sustain a declaratory judgment action. 
                                                                                                             
* Homer Yang-hsien Hsu, University of Washington School of Law, Class of 
2011. Thank you to Professor Jane K. Winn and Professor Paul T. Meiklejohn. 
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INTRODUCTION 
 
Declaratory judgment actions are important tools for alleged 
infringers in patent litigation because they resolve uncertainty and 
prevent monetary damages from continuing to accrue for infringe-
ment. In addition, declaratory judgment actions give alleged infringers 
strategic advantages by acting as plaintiff, including the ability to 
choose a favorable forum and to enjoy the benefits of primacy and 
memorability at trial.1 The issue, however, is whether there is an actual 
controversy  such that an infringer will have standing to bring an 
action for a declaratory judgment. 
In 2007, the United States Supreme Court in MedImmune, Inc. v. 
Genentech, Inc. abandoned the two-part test traditionally applied when 
                                                                                                             
1 In trial, the plaintiff generally introduces the case (“primacy”) and delivers the 
closing statement (“memorability” or “recency”). Primacy and memorability put 
plaintiffs in a better position to convince judges or juries. 
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determining if a party has standing to bring a declaratory judgment 
action—showing (1) a reasonable basis for believing the infringer will be 
sued and (2) meaningful preparation to infringe.2 Instead the Court 
adopted a new “all circumstances” test that eliminated the first prong 
and made it easier to obtain declaratory relief in patent cases. 
However, confusion resulted when the Federal Circuit failed to 
consistently apply the new test and instead considered certain elements 
of the two-part test from time to time. 
Two years after MedImmune, in Hewlett-Packard Co. v. Acceleron 
LLC,3 the Federal Circuit eliminated some of that confusion when it 
followed the “all circumstances” test to determine whether an alleged 
infringer had standing to bring a declaratory judgment action. The 
Hewlett-Packard case is important not only because it confirms that the 
Federal Circuit follows the “all circumstances” test set out in Med-
Immune, but also because it sheds light on the trend that the Federal 
Circuit treats patent-holding companies differently from patentees who 
actually use their patents. 
 
I. DECLARATORY JUDGMENT ACTIONS IN PATENT DISPUTES 
 
The Declaratory Judgment Act4 authorized federal courts to 
provide legal remedies to interested parties who have an “actual 
controversy” within the meaning of Article III of the U.S. Consti-
tution.5 Congress intended declaratory relief as an alternative to 
injunction in cases where injunctive relief is unavailable.6 The 
objectives of the Declaratory Judgment Act are (1) to avoid accrual of 
avoidable damages to those who are not certain of their rights, (2) to 
afford early adjudication without waiting until the adversary decides to 
bring a patent infringement lawsuit, and (3) to clarify legal relation-
ships before they have been disturbed or a party’s rights have been 
                                                                                                             
2 MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (2007). 
3 Hewlett-Packard Co. v. Acceleron LLC, 587 F.3d 1358, 1361 (Fed. Cir. 2009). 
4 28 U.S.C. §§ 2201-2202 (2006).  
5 U.S. Const., art. III, § 2. 
6 Steffel v. Thompson, 415 U.S. 452 (1974). 
3
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violated.7 
Courts do not have jurisdiction to deliver advisory opinions on 
questions that are abstract or hypothetical in nature, so only interested 
parties who have an actual controversy are eligible to bring a suit.8 The 
term “actual” is one of emphasis rather than of definition, which 
means that the controversy should be real in the constitutional sense.9 
In other words, the Declaratory Judgment Act requires that actions for 
declaratory judgment meet the same test for “case or controversy” as 
required for conventional suits under Article III federal jurisdiction.10 
Determining whether there is an actual controversy is essential to 
deciding whether a party has standing to sue.11 
Declaratory judgment actions are frequently used in patent 
infringement suits as both shields and swords. Employed as a shield, a 
defendant can bring counterclaims for a declaration of invalidity, 
unenforceability, and non-infringement. In contrast, when used as a 
sword, the declaratory judgment action allows the alleged infringer to 
file suit before the patentee brings an infringement action. This can 
prevent damages from continuing to accrue and can help businesses 
make risk assessments. 
The advantages of declaratory judgments for alleged patent 
infringers are many. For example, declaratory judgment actions allow 
                                                                                                             
7 Travelers Ins. Co. v. Davis, 490 F.2d 536, 543 (9th Cir. 1974). 
8 Aetna Life Ins. Co. v. Haworth, 300 U.S. 227 (1937). 
9 Id. at 239-40. 
10 See, e.g., Jennifer R. Saionz, Declaratory Judgment Actions in Patent Cases: The 
Federal Circuit's Response to MedImmune v. Genentech, 23 BERKELEY TECH. L.J. 161, 161 
(2008). 
11 However, even if an actual controversy exists, courts still have discretion to 
hear declaratory judgment action. But the district court must have a sound basis for 
refusing jurisdiction over a declaratory judgment action. See Wilton v. Seven Falls 
Co., 515 U.S. 277, 289-90 (1995). See also Elecs. for Imaging, Inc. v. Coyle, 394 F.3d 
1341, 1345-46 (Fed. Cir. 2005); Capo, Inc. v. Dioptics Med. Prod., Inc., 387 F.3d 
1352, 1357 (Fed. Cir. 2004) (“There must be a sound basis for refusing to adjudicate 
an actual controversy, for the policy of the Act is to enable resolution of active 
disputes.”); Genentech v. Eli Lilly & Co., 998 F.2d 931, 937 (Fed. Cir. 1993) 
(“When there is an actual controversy and a declaratory judgment would settle the 
legal relations in dispute and afford relief from uncertainty or insecurity, in the usual 
circumstance the declaratory action is not subject to dismissal.”). 
4
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alleged infringers to eliminate uncertainty regarding potential patent 
infringements. In addition, bringing a declaratory judgment action 
gives an alleged infringer the opportunity to choose a favorable place 
to sue and to control aspects pertaining to litigation such as forum 
convenience, potential jury pools, local court rules, trial speed, and 
court sophistication regarding patent cases. Finally, declaratory judg-
ment actions allow alleged infringers to better control business risks. 
The declaratory judgment action is an equitable remedy. This 
means that the court has discretion to decline the declaratory judg-
ment action jurisdiction if it deems appropriate, even if a justiciable 
controversy exists.12 
 
II. FROM TWO-PART TO “ALL CIRCUMSTANCES”: HISTORY OF 
DECLARATORY JUDGMENT ACTIONS AND SUPREME COURT’S 
DECISION IN MEDIMMUNE 
 
The Supreme Court first established the meaning of “actual 
controversy” under the Declaratory Judgment Act in Aetna Life 
Insurance Co. v. Haworth.13 In Aetna, the Court defined the limitation 
of “actual controversy” to mean controversies appropriate for judicial 
determination by a court described in Article III of the Constitution.14 
The Court stated that “the controversy must be definite and concrete, 
                                                                                                             
12 See, e.g., EMC Corp. v. Norand Corp., 89 F.3d 807, 810 (Fed. Cir. 1996) 
(“Even if there is an actual controversy, the district court is not required to exercise 
declaratory judgment jurisdiction, but has discretion to decline that jurisdiction.”). 
13 Aetna Life, 300 U.S. 227 (1937). In Aetna Life, the declaratory judgment 
defendant, Haworth, had purchased life insurance policies from Aetna Life 
Insurance Company. The policies provided that upon proof of total and permanent 
disability, the insured was no longer required to pay additional premiums, yet the 
insurance policies would remain in force. Haworth allegedly ceased payment of 
premiums and provided Aetna with documentation of disability. Haworth did not 
initiate suit against Aetna or make any threats to do so. Aetna sued Haworth under 
the Declaratory Judgment Act, seeking to have the policies declared null and void for 
nonpayment. 
14 Id. at 239-40 (“The Declaratory Judgment Act of 1934, in its limitation to 
‘cases of actual controversy,’ manifestly has regard to the constitutional provision and 
is operative only in respect to controversies which are such in the constitutional 
sense. The word ‘actual’ is one of emphasis rather than of definition.”). 
5
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touching the legal relations of parties having adverse legal interests.”15 
Later, in Maryland Casualty Co. v. Pacific Coal & Oil Co., the 
Supreme Court stated that the presence of an “actual controversy” 
within the meaning of the statute depends on “whether the facts 
alleged, under all the circumstances, show that there is a substantial 
controversy, between parties having adverse legal interests, of sufficient 
immediacy and reality to warrant the issuance of a declaratory 
judgment.”16 
Based on this guidance, the United States Court of Appeals for the 
Federal Circuit tried to develop a two-part test to assess whether an 
actual controversy exists.17 This dual prong test required: (1) an explicit 
threat or other action by the patentee that creates a reasonable 
apprehension on the part of the declaratory judgment plaintiff that 
they will face an infringement suit (the “reasonable apprehension” 
prong) and (2) present activity by the declaratory judgment plaintiff 
which could constitute infringement, or concrete steps taken with the 
intent to conduct such activity (the “meaningful preparation” prong).18 
Under the first element, the defendant’s (patent holder’s) actions 
needed to create, in the alleged infringer, a reasonable apprehension of 
an infringement suit.19 An express accusation of infringement was 
sufficient, but not necessary, to create a reasonable apprehension of 
suit.20 For the second element, the plaintiff (alleged infringer) needed 
to engage in an activity that would be subject to an infringement 
                                                                                                             
15 Id. at 240-241. 
16 Maryland Casualty Co. v. Pacific Coal & Oil Co., 312 U.S. 270 (1941); see 
also Arrowhead Indus. Water, Inc. v. Ecolochem, Inc., 846 F.2d 731 (Fed. Cir.1988); 
see also EMC Corp. v. Norand Corp., 89 F.3d 807, 810 (Fed. Cir. 1996). 
17 See C.R. Bard, Inc. v. Schwartz, 716 F.2d 874, 879 (Fed. Cir. 1983) (“Courts 
have interpreted the controversy requirement in the patent field to generally mean 
that the declaratory plaintiff has sufficient interest in the controversy and that there 
is a reasonable threat that the patentee or licensor will bring an infringement suit 
against the alleged infringer.”). 
18 Teva Pharm. USA, Inc. v. Novartis Pharm. Corp., 482 F.3d 1330, 1339 (Fed. 
Cir. 2007); see also Arrowhead Indus. Water, Inc. v. Ecolochem, Inc., 846 F.2d 731, 
737 (Fed. Cir. 1988). 
19 See Arrowhead 846 F.2d at 736. 
20 See Goodyear Tire & Rubber Co. v. Releasomers, Inc., 824 F.2d 953, 956 
(Fed. Cir. 1987). 
6
Washington Journal of Law, Technology & Arts, Vol. 6, Iss. 2 [2010], Art. 2
https://digitalcommons.law.uw.edu/wjlta/vol6/iss2/2
2010] NEUTRALIZING ACTUAL CONTROVERSY 99 
accusation or have made “meaningful preparation” for such an 
activity.21 
In MedImmune, Inc. v. Genentech, Inc., the Supreme Court held that 
the Federal Circuit’s two-part test was inconsistent with Supreme 
Court precedent, explicitly overruling the “reasonable apprehension” 
element of the test and implicitly overruling the second part as well.22 
The Supreme Court replaced the Federal Circuit’s formalistic 
approach with a “totality of the circumstances” approach that inquires 
into the parties’ legal interests to determine whether there is an actual 
controversy.23 
The Court held that although MedImmune paid royalties to 
Genentech to eliminate the risk of an infringement suit, it was not 
prohibited from also filing a declaratory judgment action for non-
infringement, invalidity, and unenforceability.24 The Supreme Court 
reasoned that Article III’s justiciable controversy requirement did not 
require an unwilling licensee to risk liability for infringement, with 
potential treble damages, before it could obtain a declaration of 
actively contested legal rights.25 In short, the plaintiff of a declaratory 
judgment action does not have to choose between abandoning a claim 
of right and facing the threat of injury.26 
Although the Supreme Court did not explicitly overrule both 
prongs of the two-part test, the Court indicated in a footnote that the 
Federal Circuit’s two-part test conflicted with Supreme Court 
precedent.27 Regardless of the Court’s ultimate decision about the two-
                                                                                                             
21 See Arrowhead, 846 F.2d at 736. 
22 MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118, 132 n. 11 (2007). See also 
SanDisk Corp. v. STMicroelectronics, Inc., 480 F.3d 1372, 1380 n. 2 (Fed. Cir. 
2007) (“We therefore leave to another day the effect of MedImmune, if any, on the 
second prong.”). 
23 MedImmune, 127 S. Ct. at 771. 
24 Id. 
25 Id. at 775 (“The rule that a plaintiff must destroy a large building, bet the 
farm, or (as here) risk treble damages and the loss of 80 percent of its business before 
seeking a declaration of its actively contested legal rights finds no support in Article 
III.”). 
26 Id. at 772-73. 
27 Id. at 774 n. 11. 
7
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part test, it was clear from the opinion that the “all circumstances” test 
should apply in the future.28 It has, however, taken the Federal Circuit 
a number of years to completely abandon the two-prong test and 
embrace the “all circumstances” analysis. 
 
III. AFTER MEDIMMUNE: CONFUSION CAUSED BY CONTINUOUS USE 
OF ELEMENTS IN THE IMPROPER TWO-PART TEST 
 
After MedImmune, the Federal Circuit initially followed aspects of 
the new “all circumstances” test set out by the Supreme Court. But 
occasionally the Federal Circuit would continue to apply the tradi-
tional two-part test, thereby leading to some confusion because the 
Supreme Court had held that test was improper. This confusion, 
however, was eventually eliminated by Hewlett-Packard Co. v. Acceleron 
LLC, a 2009 Federal Circuit case that clearly follows the “all 
circumstances” test of MedImmune. With that decision, the Federal 
Circuit signaled to future litigants that the “all circumstances” test will 
now be used going forward.  
 
A.  Initial Adherence to the “All Circumstances” Test 
 
In SanDisk Corp. v. STMicroelectronics, Inc., the Federal Circuit 
considered a dispute between competitors who had entered into 
negotiations to cross-license their patents.29 When negotiations began 
to break down, SanDisk filed suit, alleging infringement of one of its 
patents and seeking a declaratory judgment of non-infringement and 
invalidity of the fourteen STMicroelectronics (ST) patents that had 
been discussed during the cross-licensing negotiations.30 ST filed a 
motion to dismiss for lack of subject matter jurisdiction. The district 
court granted the motion, holding that no actual case or controversy 
                                                                                                             
28 Id. at 771 (“Basically, the question in each case is whether the facts alleged, 
under all the circumstances, show that there is a substantial controversy, between 
parties having adverse legal interests, of sufficient immediacy and reality to warrant 
the issuance of a declaratory judgment.”). 
29 SanDisk, 480 F.3d 1372 (Fed. Cir. 2007). 
30 Id. at 1376. 
8
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existed under the declaratory judgment action because SanDisk did 
not “reasonably apprehend” suit.31 
The Federal Circuit reversed. The court determined that it had 
jurisdiction in a declaratory judgment action where cross-licensing 
negotiations were ongoing.32 Furthermore, the court held that SanDisk 
could bring a declaratory judgment action before it received explicit 
threats of litigation.33 “[W]here a patentee asserts rights under a patent 
based on certain identified ongoing or planned activity of another 
party, and where that party contends that it has the right to engage in 
the accused activity without license,” the court has jurisdiction over the 
action “and the party need not risk a suit for infringement by engaging 
in the identified activity before seeking a declaration of its legal 
rights.”34 The Federal Circuit observed that this holding was consistent 
with MedImmune.35 
In addition, the Federal Circuit acknowledged that MedImmune 
overruled the “reasonable apprehension” element of the two-part test,36 
but the court observed that MedImmune did not address the 
“meaningful preparation” element. The Federal Circuit declined to 
consider the effect of MedImmune on the second element at that time.37 
                                                                                                             
31 Id. 
32 Id. at 1383. 
33 Id. at 1381 (“We hold only that where a patentee asserts rights under a patent 
based on certain identified ongoing or planned activity of another party, and where 
that party contends that it has the right to engage in the accused activity without 
license, an Article III case or controversy will arise and the party need not risk a suit 
for infringement by engaging in the identified activity before seeking a declaration of 
its legal rights.”). 
34 Id. See also Cygnus Therapeutic Sys. v. ALZA Corp., 92 F.3d 1153 (Fed. Cir. 
1996) (holding that declaratory judgment jurisdiction was not supported where the 
“patentee does nothing more than exercise its lawful commercial prerogatives and, in 
so doing, puts a competitor in the position of having to choose between abandoning 
a particular business venture or bringing matters to a head by engaging in arguably 
infringing activity”). 
35 SanDisk, 480 F.3d at 1381-82. 
36 Id. at 1380. 
37 Id. at 1380 n. 2 (“We therefore leave to another day the effect of MedImmune, 
if any, on the second prong.”). The second prong asks whether the plaintiff engaged 
in infringing activity or meaningfully prepared to engage in such activity. 
9
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In short, the Federal Circuit failed to completely embrace the Supreme 
Court’s “all circumstances” test in SanDisk. 
That same year, in Teva Pharmaceuticals USA, Inc. v. Novartis 
Pharmaceuticals Corp., the Federal Circuit addressed a dispute between 
a generic (Teva) and a brand name (Novartis) pharmaceutical 
company.38 Unlike SanDisk Corp., however, Teva Pharmaceuticals moved 
closer towards the “all circumstances” test. 
In Teva Pharmaceuticals, Novartis filed a New Drug Application 
(NDA) with the FDA for the drug Famvir and listed five patents 
covering the drug: one relating to its composition and four relating to 
therapeutic methods.39 Later, Teva filed an Abbreviated New Drug 
Application (ANDA) for a generic version of Famvir and certified that 
Teva’s drug did not infringe upon Novartis’ patents or that the patents 
were invalid.40 
Novartis sued Teva for infringement of its composition patent, but 
not the method patents.41 In a separate suit, Teva brought a declaratory 
judgment action for invalidity and non-infringement of the unasserted 
method patents.42 Because Novartis had not taken any actions or made 
any threats to enforce the method patents, the district court held that 
                                                                                                             
38 Teva Pharm. USA, Inc. v. Novartis Pharm. Corp., 482 F.3d 1330 (Fed. Cir. 2007). 
39 Teva, 482 F.3d at 1334. The Federal Food, Drug, and Cosmetic Act provides 
generic pharmaceutical manufacturers with a shortened approval process for 
marketing generic drugs. Federal Food, Drug, and Cosmetic Act of 1938, Pub. L. No. 
75-717, 52 Stat. 1040 (codified as amended at 21 U.S.C. §§ 301-399 (2000 & Supp. 
IV 2004)); Drug Price Competition and Patent Term Restoration Act of 1984, Pub. 
L. No. 98-417, 98 Stat. 1585 (1984) (codified in relevant parts at 21 U.S.C. § 355 
and 35 U.S.C. § 271(e) (2000 & Supp. III 2003)).  
40 Id. The ANDA filed by generic manufacturers allows utilization of the safety 
and efficacy data submitted for the equivalent branded drug’s previously filed NDA. 
21 U.S.C. § 355(j) (2000 & Supp. III 2003). As an added incentive to produce 
generic drugs, the first company to file an ANDA for a particular drug is granted a 
180-day period of market exclusivity before other generic manufacturers may enter 
the market. The 180-day period of market exclusivity begins to run either when the 
generic drug begins commercial marketing or when a court declares the patent cover-
ing the branded drug invalid.  
41 Id. at 1334-35. 
42 Teva Pharm. USA, Inc. v. Novartis Pharm. Corp., No. 05-2881 JLL, 2005 U.S. 
Dist. LEXIS 38649 (D. N.J. Dec. 12, 2005). 
10
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no justiciable controversy existed and dismissed the case for lack of 
subject matter jurisdiction.43 
The Federal Circuit looked at the totality of the circumstances 
under which Teva had brought suit and reversed the district court, 
holding that Teva had a justiciable controversy under the MedImmune 
standard.44 The court emphasized that “Novartis created a present and 
actual ‘controversy’ by choosing to sue . . . on Teva’s single act of 
infringement, thereby placing into actual dispute the soundness of 
Teva’s ANDA and Teva’s ability to secure approval of the ANDA.”45 
Though the Novartis-initiated suit was a different case from Teva’s 
declaratory judgment action, litigation over the composition patent 
and the method patents necessarily involved the same technology, the 
same parties, and related patents. Thus, the Federal Circuit concluded 
that there was a justiciable controversy.46  
 
B.  Federal Circuit Still Considers Factors of the Improper Two-Part Test 
 
Although the Federal Circuit began to consider “all circumstances” 
in Teva Pharmaceuticals when determining declaratory judgment 
jurisdiction, it seems that the traditional two-part test did not 
completely disappear. Just a year after the SanDisk and Teva cases, in 
2008, the Federal Circuit seemed to resurrect at least part of its two-
part test.  
In Cat Tech LLC v. TubeMaster, Inc.,47 the Federal Circuit found 
that the second prong of “meaningful preparation” was still intact—at 
least as a factor used in determining whether a dispute is immediate 
and real. 
Cat Tech had brought suit against TubeMaster for patent 
infringement. TubeMaster counterclaimed, seeking a declaration that 
its devices did not infringe Cat Tech’s patent and that the patent was 
invalid and unenforceable. Cat Tech subsequently amended its comp-
                                                                                                             
43 Id. at 9. 
44 Teva, 482 F.3d at 1340. 
45 Id. 
46 Id. 
47 Cat Tech LLC v. TubeMaster, Inc., 528 F.3d 871 (Fed. Cir. 2008), 
11
Hsu: Neutralizing Actual Controversy: How Patent Holders Can Reduce th
Published by UW Law Digital Commons, 2010
104 WASHINGTON JOURNAL OF LAW, TECHNOLOGY & ARTS  [Vol. 6:2 
laint, seeking a declaratory judgment of infringement.48 The district 
court concluded that TubeMaster did not infringe49 so Cat Tech 
appealed. 
On appeal, the Federal Circuit affirmed, but in doing so seemed to 
reinvigorate the “meaningful preparation element.” The Federal 
Circuit concluded that although MedImmune articulated a “more 
lenient legal standard” for the availability of declaratory judgment 
relief in patent cases,50 the issue of whether there has been “meaning-
ful preparation” to conduct potentially infringing activity remains an 
important element when considering the “totality of circumstances” 
for purposes of the MedImmune test.51 In other words, if a declaratory 
judgment plaintiff has not taken significant, concrete steps to conduct 
infringing activity, the dispute is neither “immediate” nor “real” and 
the requirements for justiciability have not been met.52 In contrast, 
from the Federal Circuit’s point of view, the immediacy requirement 
for a declaratory judgment could be satisfied if the alleged infringer 
took significant, concrete steps to use the potentially infringing design, 
like TubeMaster did in this case.53 
In addition to Cat Tech, there are two other cases showing that the 
Federal Circuit appeared to be retreating from its acceptance of the “all 
circumstances” test in Sandisk. In Janssen Pharmaceutica, N.V. v. Apotex, 
Inc.,54 the Federal Circuit required more than speculative fear of harm 
to establish that the dispute was “definite and concrete.”55 In Prasco, 
LLC v. Medicis Pharm. Corp., the Federal Circuit required the plaintiff 
in a declaratory judgment action to show an affirmative act by the 
                                                                                                             
48 Cat Tech, 528 F.3d at 878. 
49 Id. 
50 Id. (quoting Micron Tech v. MOSAID Tech., 518 F.3d 897, 902 (Fed. Cir. 
2008)). 
51 Id. (quoting Teva, 482 F.3d at 1339). 
52 Id. (quoting Lang v. Pac. Marine & Supply Co., 895 F.2d 761, 764 (Fed Cir. 
1990) (emphasizing that the test for justiciability “looks to the accused infringer’s 
conduct and ensures that the controversy is sufficiently real and substantial”)). 
53 Cat Tech, 528 F.3d at 882. 
54 Janssen Pharmaceutica, N.V. v. Apotex, Inc., 540 F.3d 1353 (Fed. Cir. 2008). 
55 Id. at 1362-63. 
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patentee that demonstrated intent to sue.56 Both of these holdings are 
reminiscent of the Federal Circuit’s traditional two-part test. 
 
IV. HEWLETT-PACKARD AND THE FEDERAL CIRCUIT’S RETURN TO 
MEDIMMUNE 
 
In 2009, the Federal Circuit once again returned to the “all 
circumstances” test, but this time with more conviction. In Hewlett-
Packard Co. v. Acceleron LLC,57 the Federal Circuit held that when 
Acceleron, the patent-holder, offered a potential patent license to 
Hewlett-Packard without expressly accusing infringement, that contact 
was sufficient to give Hewlett-Packard standing to bring a declaratory 
judgment action.  
Acceleron had contacted Hewlett-Packard on September 14, 2007 
to offer a patent license with a two-week deadline for a response. 
Acceleron requested an opportunity to discuss the potential license of 
a patent recently acquired and asked Hewlett-Packard not to use any 
information exchanged in the discussion in any litigation. Two weeks 
later, Hewlett-Packard responded by agreeing not to file a declaratory 
judgment action for 120 days if Acceleron similarly agreed not to file 
an infringement action during the same period. Acceleron then 
responded, stating that it did not believe Hewlett-Packard had any 
basis for filing a declaratory judgment action. Once again, it imposed a 
two-week period for Hewlett-Packard to accept the patent license offer.  
On October 17th, Hewlett-Packard filed a declaratory judgment 
suit in the District Court for the District of Delaware. Acceleron 
moved to dismiss for lack of subject matter jurisdiction. On March 11, 
2009, the district court granted Acceleron’s motion, based on the 
following factual filings: (1) Acceleron never proposed a confidentiality 
agreement, and (2) Acceleron never accepted Hewlett-Packard’s 120-
day -standstill proposal and never provided a counter-proposal or other 
assurance it would not sue Hewlett-Packard. Hewlett-Packard appealed 
the dismissal of its declaratory judgment action. 
                                                                                                             
56 Prasco, L.L.C. v. Medicis Pharm. Corp., 537 F.3d 1329, 1338 (Fed. Cir. 
2008). 
57 Hewlett-Packard Co. v. Acceleron LLC, 587 F.3d 1358 (Fed. Cir. 2009). 
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On appeal, the Federal Circuit reversed the dismissal after holding 
a declaratory judgment action cannot be defeated simply by using a 
correspondence that “avoids the magic words such as ‘litigation’ or 
‘infringement.’”58 The Federal Circuit further recognized that it is 
implausible (especially after MedImmune and several post-MedImmune 
decisions) to expect that a competent lawyer drafting such corres-
pondence for a patent owner would identify specific claims, present 
claim charts, and explicitly allege infringement.59 
On the other hand, the court noted that a communication from a 
patent owner to another party that merely identifies its patent and the 
other party’s product line, without more communications, cannot 
establish adverse legal interests between the parties, let alone the 
existence of a “definite and concrete” dispute. More communication is 
required to establish declaratory judgment jurisdiction.60  
The Federal Circuit noted that the test for declaratory judgment 
jurisdiction in patent cases is objective.61 Indeed, it is the objective 
words and actions of the patent holder that are controlling.62 Thus, 
conduct that can be reasonably inferred as demonstrating intent to 
enforce a patent can create declaratory judgment jurisdiction. 
The Federal Circuit further observed that Acceleron was solely a 
licensing entity, and without enforcement it received no benefits from 
its patents.63 In the Federal Circuit’s view, this added significance to 
the fact that Acceleron refused Hewlett-Packard’s request for a mutual 
standstill—and such a limited standstill is distinguishable from a 
covenant not to sue.64 
The facts of this case, when viewed objectively and in totality, 
showed to the Federal Circuit’s satisfaction that Acceleron took the 
                                                                                                             
58 Id. 
59 Id. 
60 Id. at 1362. 
61 Id. at 1363 (quoting Arrowhead Indus. Water, Inc. v. Ecolochem, Inc., 846 
F.2d 731, 736 (Fed.Cir.1988)). 
62 Id. (quoting BP Chems. v. Union Carbide Corp., 4 F.3d 975, 979 (Fed. Cir. 
1993)). 
63 Id. at 1364. 
64 Id. (such as that cited by the district court in Prasco, LLC, v. Medicis 
Pharmaceutical Corp., 537 F.3d 1329, 1341 (Fed. Cir. 2008)). 
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affirmative step of twice contacting Hewlett-Packard directly and 
making an implied assertion of its patent right against Hewlett-
Packard. In other words, Acceleron did not directly accuse Hewlett-
Packard of patent infringement, but it did (1) indicate that its patents 
were “relevant” to Hewlett-Packard products, (2) insist that Hewlett-
Packard’s response must come within two weeks, and (3) ask Hewlett-
Packard not to file a declaratory judgment action. Thus, the Federal 
Circuit held that it is reasonable for Hewlett-Packard to interpret 
Acceleron’s letters as implicitly asserting its patent rights under the 
circumstances,65 and Hewlett-Packard was eligible to bring a 
declaratory judgment action.  
The Hewlett-Packard decision is important because the Federal 
Circuit confirmed again—and, hopefully, once and for all—that the “all 
circumstances” test should be applied to determine jurisdiction over 
declaratory judgment actions.66 It is also noteworthy that Federal 
Circuit considered that a patentee is “solely a licensing entity, and 
without enforcement it receives no benefits from its patents.”67 This 
signals that the Federal Court may treat patent holders who actually 
sell patented products more favorably than patent holding entities who 
only license patents. 
 
V. IMPLICATION OF HEWLETT-PACKARD—“ALL CIRCUMSTANCES” TEST 
CONFIRMED & PATENT HOLDING ENTITIES BEWARE 
 
The Hewlett-Packard case confirms that the Federal Circuit will 
apply the “all circumstances” test in determining whether an actual 
controversy exists to satisfy the standing requirement for declaratory 
judgment actions by alleged infringers during licensing negotiation. An 
actual controversy occurs when the patent holder and the alleged 
infringer have different opinions about whether accused products fall 
within the scope of the patents. Patent holders should therefore 
consider the risk of facing a declaratory judgment action if adverse 
                                                                                                             
65 Id. 
66 Id. (”Our decision in this case undoubtedly marks a shift from past declaratory 
judgment cases”). 
67 Id. 
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opinions form during licensing negotiations. Patentees may want to 
arrange certain nondisclosure agreements (NDAs) between parties 
prior to the licensing negotiation. Although NDAs may not completely 
prevent the alleged infringer from bringing declaratory judgment 
actions, they may provide a contractual basis for a remedy if the 
accused infringer discloses materials in further declaratory judgment 
actions.  
Another strategy would be for patentees to bring an infringement 
suit before initiating the licensing negotiation. The patentee can 
generally file a complaint first without serving the accused infringer to 
allow both parties to have a chance to negotiate a possible license. By 
doing so, the patentees can still choose favorable fora and enjoy the 
advantages of primacy and memorability in litigation.  
Patent holding companies should expect that the courts will take 
into consideration that such companies generally license their patents 
rather than using them in other ways. The Federal Circuit reasoned 
that because licensing is how patent holding companies use their 
patents, the “actual controversy” occurs more easily when adverse 
positions are formed during licensing negotiation. If the patentee is a 
holding company, which means that patentee can only enforce the 
patent right by licensing, that status is also a factor to consider when 
determining declaratory judgment jurisdiction. 
 
CONCLUSION 
 
Hewlett-Packard signaled the Federal Circuit’s decision to finally 
embrace the “all circumstances” test from MedImmune in determining 
whether there is an actual controversy to establish standing for a 
declaratory judgment action over patent infringement. Communica-
tion merely identifying patents and products is insufficient to establish 
adverse legal interests or an actual controversy. Instead, the courts will 
consider all circumstances under an objective standard to determine 
whether there is a declaratory judgment jurisdiction. If the patentee is 
a holding company, the courts may more easily find a sufficient 
controversy exists over a licensing negotiation. On the other hand, the 
courts still have discretion whether to hear a declaratory judgment 
action case even if the actual controversy element is met. To preserve 
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the advantage of choosing favorable fora, it is recommended that 
patentees bring any applicable infringement suit before initiating 
license negotiations. 
 
PRACTICE POINTERS 
 
 Patentees should avoid ultimatums or strict deadlines during 
license negotiation. During the license negotiation, the patentee 
should be aware that the accused infringer might use every 
correspondence and communication as evidence to show actual 
controversy between the parties. Demands for responses within 
specific timeframes could suggest a sufficient controversy has 
arisen. 
 Patentees should avoid disclosing patents not intended. Patentees 
should not disclose unrelated patents during license negotiation 
because such disclosure may create a basis for the accused infringer 
to bring a declaratory judgment action against that unrelated 
patent. 
 Patentees should consider executing nondisclosure agreements 
(NDAs). Before any license negotiation, both parties should 
consider executing a NDA to prevent disclosure of any 
communication during negotiation. Such an agreement may not 
effectively prevent the accused infringers from bringing declaratory 
judgment actions, but the NDA could provide a contractual basis 
for possible damage claims if one party breaches. 
 Patentees should consider bringing suit before license negotiation. 
Based on the modern “all circumstances” test, it is easier for 
accused infringers to bring a declaratory judgment action than 
before. To preserve the advantages of choosing favorable fora, 
patentees may want to bring an infringement suit before license 
negotiations. 
 Patentees should challenge, on equitable grounds, declaratory 
judgment claims brought during negotiations. Patentees should 
consider asking courts to decline jurisdiction if an alleged infringer 
files a declaratory judgment action during licensing negotiations. 
Since a declaratory judgment action is an equitable remedy, the 
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court can decline jurisdiction if it perceives the alleged infringer 
filed the action just to gain leverage in the licensing negotiation.  
 Patentees should negotiate penalty clauses in license agreements. 
Patentees should include penalty clauses in license agreements that 
are triggered by any attack on the patent. Possible penalties could 
include an automatic increase in royalty rates, liquidated damages, 
or termination of the license. 
18
Washington Journal of Law, Technology & Arts, Vol. 6, Iss. 2 [2010], Art. 2
https://digitalcommons.law.uw.edu/wjlta/vol6/iss2/2
